Market Overview

UPDATE: Deutsche Bank Raises PT on Aegerion Pharmaceuticals on Strong Juxtapid Uptake

Related AEGR
Aegerion Pharmaceuticals Appoints Gregory Perry as CFO
Aegerion Pharmaceuticals Announces Key Additions to Medical Affairs and Drug Safety

In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR), and raised its price target from $37.00 to $41.00.

Deutsche Bank noted, “We also have higher conviction in peds-HOFH OPP'Y. However, we are removing FC OPP'Y from numbers on limited progress so far...Given that patient uptake has robust so far, we believe there could be upside to 2013 company guidance of $15-$25M in sales. We calculate that the company can generate $13M sales in 2013 with only these 85 pts added so far.”

Aegerion Pharmaceuticals closed on Tuesday at $34.47.

Latest Ratings for AEGR

Oct 2014JefferiesDowngradesBuyHold
Oct 2014JP MorganDowngradesOverweightNeutral
Oct 2014Deutsche BankDowngradesBuyHold

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (AEGR)

Around the Web, We're Loving...

Get Benzinga's Newsletters